Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib +/- Pembrolizumab in Recurrent Ovarian Cancer
NCT02537444Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- Nov 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib in ovarian cancer, sponsored by Acerta Pharma. Started Nov 2015; status: completed.
02
Drugs
acalabrutinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02537444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537444.